EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non–small cell lung cancer

Long Xu, Haojie Si, Fenghui Zhuang, Chongwu Li, Lei Zhang, Yue Zhao, Tao Chen, Yichen Dong, Tingting Wang, Likun Hou, Tao Hu, Tianlin Sun und 7 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2025-01 · 169 (1) · 242-253.e4

DOI: 10.1016/j.jtcvs.2024.05.006 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2025-01. Verfasst von Long Xu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy, Lung Neoplasms, Neoplasm Staging. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Shanghai Municipal Hospital Development Center, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Accurately predicting response during neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer remains clinically challenging. In this study, we investigated the effectiveness of blood-based tumor mutational burden (bTMB) and a deep learning (DL) model in predicting major pathologic response (MPR) and survival from a phase 2 trial. METHODS: Blood samples were prospectively collected from 45 patients with stage IIIA (N2) non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy. An integrated model, combining the computed tomography-based DL score, bTMB, and clinical factors, was developed to predict tumor response to neoadjuvant chemoimmunotherapy. RESULTS: At baseline, bTMB were detected in 77.8% (35 of 45) of patients. Baseline bTMB ≥11 mutations/megabase was associated with significantly greater MPR rates (77.8% vs 38.5%, P = .042), and longer disease-free survival (P = .043), but not overall survival (P = .131), compared with bTMB

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNeoadjuvant TherapyLung NeoplasmsNeoplasm StagingHumansMaleFemaleMiddle AgedAgedMutationTreatment OutcomeBiomarkers, TumorImmunotherapyPredictive Value of TestsProspective StudiesChemotherapy, AdjuvantDeep LearningCirculating Tumor DNAPneumonectomy

Stichwörter der Autor:innen

blood-based tumor mutational burdencirculating tumor DNAdeep learningneoadjuvant chemoimmunotherapynon–small cell lung cancer

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Department of Medicine, Amoy Diagnostics Co, Ltd, Xiamen, China.
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: dpzhao@tongji.edu.cn.
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: chenthoracic@163.com.

Förderung

  • National Key Research and Development Program of China
  • Shanghai Municipal Hospital Development Center
  • National Natural Science Foundation of China

Zitieren

APA

Xu, L., Si, H., Zhuang, F., Li, C., Zhang, L., Zhao, Y., Chen, T., Dong, Y., Wang, T., Hou, L., Hu, T., Sun, T., She, Y., Hu, X., Xie, D., Wu, J., Wu, C., Zhao, D., & Chen, C. (2025). Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery, 169(1), 242-253.e4. https://doi.org/10.1016/j.jtcvs.2024.05.006

Vancouver

Xu L, Si H, Zhuang F, Li C, Zhang L, Zhao Y, et al. Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery. 2025;169(1):242-253.e4. doi:10.1016/j.jtcvs.2024.05.006

BibTeX
@article{Xu2025,
  author = {Xu, Long and Si, Haojie and Zhuang, Fenghui and Li, Chongwu and Zhang, Lei and Zhao, Yue and Chen, Tao and Dong, Yichen and Wang, Tingting and Hou, Likun and Hu, Tao and Sun, Tianlin and She, Yunlang and Hu, Xuefei and Xie, Dong and Wu, Junqi and Wu, Chunyan and Zhao, Deping and Chen, Chang},
  title = {Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non–small cell lung cancer},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2025},
  volume = {169},
  number = {1},
  pages = {242--253.e4},
  doi = {10.1016/j.jtcvs.2024.05.006}
}
Kostenlos starten →